Android app on Google Play

Baird Q2 Preview on Affymax, Inc. (AFFY): Expectations are Low, But Survey Highlights Positive Data

July 13, 2012 12:13 PM EDT Send to a Friend
Get Alerts AFFY Hot Sheet
Price: $0.24 +14.29%

Rating Summary:
    6 Buy, 4 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 4 | New: 7
Trade AFFY Now!
Join SI Premium – FREE
Baird reiterates an 'Outperform' on Affymax, Inc. (NASDAQ: AFFY), new price target of $18.00.

Analyst, Christopher Raymond, said, "Heading into Q212 earnings, (anticipate early August), we think expectations are low, given late April launch/traditionally slow nephrology ramps. However, as a new survey highlights, current Omontys use is measurable and expected uptake is meaningfully ahead of our model. Given nephrologists' historical tendencies to overstate preference-share, and given that dialysis is highly contract-driven, we wouldn't necessarily go overboard on these data. Nonetheless, this feedback is encouraging and supports our anticipation of a successful launch."

For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.

Shares of Affymax, Inc. closed at $14.24 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird, Earnings

Add Your Comment